The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients
Abstract
The coenzyme nicotinamide adenine dinucleotide (NADH) has been used in an open label trial as novel medication in 34 patients with Parkinson's disease, using an intravenous administration technique. In all patients a beneficial clinical effect was observed. 21 patients (61.7%) showed a very good (better than 30%) improvement of disability, 13 patients (38.3%) a moderate (up to 30%) improvement. Concomitant with the improvement of the disability the urine level of homovanillic acid (HVA) increased significantly in all patients (in some patients by more than a 100%). The daily "on phases" of the patients could be increased from 2 up to 9 hours in the individual patients by NADH administration.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NADH has shown beneficial effects on movement in PD.
“With relation to PD, NADH has shown beneficial effects on movement.”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Birkmayer et al., 1989
In an early study, intravenous NADH at 25 mg/day for 4 days in 34 PD patients produced dramatic benefits in 21 patients (61.7%) and moderate motor improvement in the remaining 13.
“An early study using NADH (intravenous administration, 25 mg/day) in 34 PD patients for 4 days, reported that 21 patients (61.7%) showed dramatic benefits, while the remaining 13 PD patients showed moderate improvement of motor deficits”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Birkmayer et al., 1989
Cites
BIOSYNTHESIS AND METABOLISM OF TETRAHYDROBIOPTERIN AND MOLYBDOPTERIN
Nichol, C. A., Smith, G. K., & Duch, D. S. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.003501 · Cited by 551 · see citing works
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].
Birkmayer, W., & Hornykiewicz, O. (1961) · PubMed · Cited by 529 · see citing works
Self-citationThe neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd, K. G., Davidson, L., & Hornykiewicz, O. (1975) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30363-0 · Cited by 400 · see citing works
Nagatsu, T., Yamaguchi, T., Kato, T., Sugimoto, T., Matsuura, S., Akino, M., Nagatsu, I., Iizuka, R., & Narabayashi, H. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90316-8 · Cited by 117 · see citing works
Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 83 · see citing works
Riederer, P. F., Rausch, W., Birkmayer, W., Jellinger, K. A., & Seemann, D. (1978) · PubMed · Cited by 57 · see citing works
Self-citationBirkmayer, W., & Riederer, P. F. (1985) · Springer eBooks · doi:10.1007/978-3-7091-2262-4 · Cited by 52 · see citing works
Self-citationDie moderne medikament�se Behandlung des Parkinsonismus
Birkmayer, W., & Neumayer, E. (1972) · Journal of Neurology · doi:10.1007/bf00316175 · Cited by 34 · see citing works
Self-citation[Alpha- methyl-P-tyrosine effect in extrapyramidal diseases].
Birkmayer, W. (1969) · PubMed · Cited by 25 · see citing works
Self-citationIron, a new aid in the treatment of Parkinson patients
Birkmayer, W., & Birkmayer, J. G. D. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243354 · Cited by 21 · see citing works
Self-citationBirkmayer, J. G. D., & Birkmayer, W. (1987) · PubMed · Cited by 12 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790 · see citing works
Neuroprotective effects of the antiparkinson drug Mucuna pruriens
Manyam, B. V., Dhanasekaran, M., & Hare, T. A. (2004) · Phytotherapy Research · doi:10.1002/ptr.1514 · Cited by 185 · see citing works
Castro‐Marrero, J., Sáez‐Francàs, N., Segundo, M. J., Calvo, N., Faro, M., Aliste, L., de Sevilla, T. F., & Alegre, J. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.07.010 · Cited by 70 · see citing works
Clinical Evidence for Targeting NAD Therapeutically
Radenković, D., Reason, & Verdin, E. M. (2020) · Pharmaceuticals · doi:10.3390/ph13090247 · Cited by 55 · see citing works
Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52 · see citing works
Kuhn, W., M�ller, T., Winkel, R., Danielczik, S., Gerstner, A., H�cker, R., Mattern, C., & Przuntek, H. (1996) · Journal of Neural Transmission · doi:10.1007/bf01271203 · Cited by 47 · see citing works
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia
Rainer, M., Kraxberger, E., Haushofer, M., Mucke, H. A. M., & Jellinger, K. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070011 · Cited by 46 · see citing works
Dehhaghi, M., Panahi, H., Kavyani, B., Heng, B., Tan, V., Braidy, N., & Guillemin, G. (2022) · Aging and Disease · doi:10.14336/ad.2021.0824 · Cited by 38 · see citing works
Nicotinamide Adenine Dinucleotide: The Redox Sensor in Aging-Related Disorders
Schiuma, G., Lara, D., Clement, J. P., Narducci, M., & Rizzo, R. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0375 · Cited by 33 · see citing works
Topical application of NADH for the treatment of rosacea and contact dermatitis
Woźniacka, A. J., Sysa‐Jędrzejowska, A., Adamus, J., & Gebicki, J. L. (2003) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2003.01118.x · Cited by 28 · see citing works
Vrečko, K., Birkmayer, J. G. D., & Krainz, J. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251205 · Cited by 26 · see citing works
Is NADH Effective in the Treatment of Parkinson??s Disease?
Swerdlow, R. H. (1998) · Drugs & Aging · doi:10.2165/00002512-199813040-00002 · Cited by 24 · see citing works
NAD augmentation as a disease-modifying strategy for neurodegeneration
Dölle, C., & Tzoulis, C. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.013 · Cited by 24 · see citing works
Kimura, N., Fukuwatari, T., Sasaki, R., & Shibata, K. (2006) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.52.142 · Cited by 22 · see citing works
Feuz, M. B., Meyer‐Ficca, M. L., & Meyer, R. G. (2023) · Cells · doi:10.3390/cells12030500 · Cited by 13 · see citing works
Primary cilia formation requires the Leigh syndrome–associated mitochondrial protein NDUFAF2
Lo, C., Liu, Z., Chen, S., Lin, F., Berneshawi, A. R., Yu, C. Q., Koo, E. B., Kowal, T. J., Ning, K., Hu, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175560 · Cited by 11 · see citing works
Zhang, J., Wang, C., & Ying, W. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000876 · Cited by 9 · see citing works
Liptrot, J., Holdup, D. W., & Phillipson, O. T. (1994) · Journal of Neural Transmission · doi:10.1007/bf01277928 · Cited by 7 · see citing works
Stabilized NADH as a Countermeasure for Jet Lag
Kay, G. G., Viirre, E., & Clark, J. B. (2001) · NASA Technical Reports Server (NASA) · Cited by 1 · see citing works
Exkurs: Neue klinische Entwicklungen
Müller, T., & Kuhn, W. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6400-6_40
The Future of Brain Protection: Natural Alternatives
Maynard, K. I. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0282-1_6
Rösler, D., Fuchs, N., Mikkeleit, K., Markolin, G., Kocher, B., Horn, J., Schrotter, K., & Wegberger, C. (2024) · Erfahrungsheilkunde · doi:10.1055/a-2257-6314
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease
Brakedal, B., SKEIE, G. O., Derad, C., Alstadhaug, K. B., Anundskås, I., Berven, H., Biermann, M., Bjørnarå, K. A., Cleuren, Y. N. T., Dalbro, S. E. J., et al. (2026) · JAMA · doi:10.1001/jama.2026.18828
- Authors
- Birkmayer, W., Birkmayer, G. J. D., Vrecko, K., Mlekusch, W., Paletta, B., & Ott, E.
- Affiliations
- University of Graz (AT)
- Venue
- Journal of Neural Transmission - Parkinson's Disease and Dementia Section
- Published
- 1989-12
- Volume
- 1
- Issue
- 4
- Pages
- 297-302
- ISSN
- 0936-3076 (ISSN-L)
- OpenAlex
- W2099766470
- Cited by
- 23
- References
- 11
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2017: 1 · 2015: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Neural Transmission - Parkinsons Disease and Dementia Section (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- NADH, NAD+, Parkinson's disease, disability, homovanillic acid, intravenous administration
- MeSH terms
- Aged, Aged, 80 and over, Homovanillic Acid, Humans, Injections, Intravenous, Middle Aged, Movement Disorders, NAD, Parkinson Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
